Analysts rate Ocugen Inc. (OCGN:NSD) with a Strong Buy rating and a $5 target

Mizuho Securities initiated with a Buy rating and $5 OCGN stock price target.

Based on the Ocugen Stock Forecast from 5 analysts, the average analyst OCGN stock price target is USD 5.40 over the next 12 months. Ocugen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of OCGN stock forecast is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Ocugen stock price was USD 2.03Ocugen stock price has changed by +0.10% over the past week, -0.61% over the past month and -70.23% over the last year.

 

About Ocugen Inc. (OCGN:NSD):

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

 

What we like:

Superior risk adjusted returns:

OCGN stock price has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings:

OCGN stock price is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt:

The company is less leveraged than its peers, and is among the top quartile, which makes it more flexible. However, do check the stock analysis and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

 

What we don’t like:

High volatility:

OCGN news shows that the total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value:

OCGN stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

OCGN news shows that the company had negative total cash flow in the most recent four quarters.

Negative free cash flow:

OCGN news shows that the company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

OCGN stock price has shown below median earnings growth in the previous 5 years compared to its sector.